Atossa Therapeutics

Atossa Therapeutics is a clinical-stage biopharmaceutical company focusing on breast cancer and other breast conditions. $ATOS

[Atossa Therapeutics @atossainc]

During Atossa Therapeutics’ KOL event, Dr. Laura Esserman discussed the potential of endoxifen as a well-tolerated therapeutic approach in breast cancer treatment.

The conversation highlighted observations around endoxifen’s tolerability and the rationale for delivering the active metabolite directly rather than relying on metabolic conversion from tamoxifen.

Replay available here: https://t.co/5ck95MR4U1 $ATOS

[Atossa Therapeutics @atossainc]

For many younger women with ER-positive breast cancer, endocrine therapy can mean years of treatment and significant quality-of-life burden.

That’s why researchers continue exploring whether newer endocrine strategies may improve tolerability while maintaining effective estrogen suppression.

https://t.co/6LzH2s1dNB $ATOS

[Atossa Therapeutics @atossainc]

In modern breast cancer research, it’s rarely just one datapoint.

Researchers increasingly evaluate endocrine therapies using multiple biologic signals together, including Ki-67, MRI tumor volume and ctDNA dynamics, to better understand whether a therapy is demonstrating meaningful activity.

Learn more: https://t.co/6LzH2s1dNB $ATOS

[Atossa Therapeutics @atossainc]

Day one of #PPMD2026.

We're proud to be a sponsor of this important event and look forward to joining conversations with the patients, families and advocates helping shape the future of Duchenne muscular dystrophy research and care. $ATOS

[Atossa Therapeutics @atossainc]

Why is ovarian function suppression often used in premenopausal ER-positive breast cancer?

Because the ovaries continue producing estrogen, endocrine therapy alone may not fully suppress tumor signaling in higher-risk disease.

Researchers continue exploring whether newer oral approaches may improve tolerability while maintaining estrogen suppression.

Learn more: https://t.co/T6vUiDAKa2 $ATOS

[Atossa Therapeutics @atossainc]

Atossa Therapeutics recently hosted a virtual KOL event with Dr. Laura Esserman focused on innovation in ER-positive breast cancer treatment.

The discussion highlighted the significant unmet need in ER-positive breast cancer, where better therapies remain urgently needed, and explored how adaptive clinical trial models and earlier endpoints may help accelerate development of treatments that improve patient outcomes while reducing unnecessary toxicity.

Watch the replay: https://t.co/5ck95MR4U1 $ATOS

[Atossa Therapeutics @atossainc]

Atossa Therapeutics is proud to sponsor and attend PPMD’s 2026 Annual Conference, June 24-27 in Orlando, FL.

We look forward to connecting with patients, families, advocates and researchers dedicated to advancing the future of Duchenne muscular dystrophy care and research.

$ATOS #PPMD2026

[Atossa Therapeutics @atossainc]

Today, Steven Quay, MD, PhD, joins Hudson Institute for a discussion of “The Code as Witness” alongside leaders from science, policy and national security.

June 15, 2026
1:00 - 2:00PM ET
Washington, D.C.

Details and registration: https://t.co/ssJQIy9XRI $ATOS

[Dr Steven Quay @quay_dr]

A chance meeting with the great, Dr. Robert Redfield, former CDC Director.

We exchanged our books and then had an extended conversation on what needs to happen to prevent the next pandemic.

He is inspiring!

[Atossa Therapeutics @atossainc]

For nearly 50 years, tamoxifen has been a cornerstone of endocrine therapy in breast cancer.

Atossa Therapeutics is evaluating a different approach through direct administration of (Z)-endoxifen, the active metabolite of tamoxifen.

CEO Dr. Steven Quay (@quay_dr) recently joined @proactive_x's Head of Broadcast Steve Darling (@stevedarling) to share insights on the science, recent #ASCO2026 presentations and what's ahead for the program.

Watch the discussion: https://t.co/0fgwc1tPk9 $ATOS

[Atossa Therapeutics @atossainc]

On June 15, Atossa Therapeutics CEO @quay_dr will join Hudson Institute in Washington, D.C., for a discussion of his new book, “The Code as Witness.”

The event will explore COVID-19 origins, scientific accountability and approaches to reducing future biological risks while preserving lifesaving biomedical research.

Register to attend: https://t.co/IHhIAL8zgz $ATOS

[Proactive @proactive_x]

Atossa Therapeutics highlights Endoxifen progress as potential Breast Cancer treatment @atossainc https://t.co/akUBYUFutZ #proactiveinvestors #nasdaq #atos #BreastCancer #Endoxifen #Biotech #Oncology #ClinicalTrials

[Atossa Therapeutics @atossainc]

Some surprises from #ASCO26 weren't scientific. 🚲

Even CEO Dr. Steven Quay found himself taking a ride in a driverless pedicab around Chicago.

We're still not sure if this changes his views on autonomous transportation, but it definitely made for a memorable conference photo. $ATOS @quay_dr

[Atossa Therapeutics @atossainc]

Atossa Therapeutics Chairman, President and CEO Dr. Steven Quay (@quay_dr ) recently joined David Bautz, PhD, Senior Biotech Analyst at @ZacksSmallCap, for a discussion on the company's ongoing clinical development efforts and future opportunities.

Tune in to the insightful conversation to learn more about Atossa's strategy and the continued advancement of (Z)-endoxifen.

Watch the full interview below.

https://t.co/3uhUblndTz $ATOS

[Atossa Therapeutics @atossainc]

Thank you to everyone who connected with the Atossa Therapeutics team during #ASCO26 in Chicago.

We were pleased to share the EVANGELINE Phase 2 trial-in-progress poster yesterday and discuss ongoing development of (Z)-endoxifen in ER+/HER2- breast cancer.

We appreciate the opportunity to exchange ideas with so many members of the oncology community and look forward to keeping these conversations going. $ATOS

[Atossa Therapeutics @atossainc]

Thank you for the opportunity to discuss Atossa's development strategy and the expanding potential of (Z)-endoxifen across oncology and rare disease indications.

[Zacks SCR @ZacksSmallCap]

$ATOS Senior Analyst @DavidBautz, PhD, sat down with @StevenQuay, MD, PhD, Chairman, President & CEO of @AtossaInc to discuss (Z)-endoxifen's potential across McCune-Albright syndrome, DMD, and breast cancer: https://t.co/5s5S2PECPI

#biotech #smallcapstocks #ceochat

[Atossa Therapeutics @atossainc]

Why is mammographic breast density (MBD) such an important focus in breast cancer prevention research?

Studies have shown that reductions in breast density may correlate with lower future breast cancer risk. That’s one reason researchers continue exploring whether low-dose endocrine approaches like (Z)-endoxifen may provide meaningful biologic activity with favorable tolerability.

Learn more about our approach: https://t.co/6LzH2s1dNB $ATOS

[Atossa Therapeutics @atossainc]

(Z)-endoxifen is a next generation therapy in development to address the limitations of legacy hormone treatments. We are dedicated to improving surgical outcomes and long term remission rates for breast cancer patients.

Learn more: https://t.co/gUC8YyA5xv $ATOS

[Atossa Therapeutics @atossainc]

Duchenne muscular dystrophy involves multiple failing biological systems beyond structural protein loss.

A newly accepted manuscript from Atossa Therapeutics in Degenerative Neurological and Neuromuscular Disease synthesizes transcriptomic and mechanistic findings exploring how (Z)-endoxifen may intersect with these overlapping biological processes.

Full update: https://t.co/4ACb2rxy6k $ATOS

[Atossa Therapeutics @atossainc]

Atossa Therapeutics was highlighted in a recent @ZacksSmallCap Research report discussing the company’s evolving development strategy for (Z)-endoxifen.

The report reviews Atossa’s rare disease programs in McCune-Albright Syndrome and Duchenne muscular dystrophy, ongoing breast cancer studies and the broader potential of (Z)-endoxifen across multiple clinical settings.

Read it here: https://t.co/veGsp4F1En $ATOS